General Information of Drug (ID: DMTLRGZ)

Drug Name
SGC-CBP30 Drug Info
Synonyms
SGC-CBP30; 1613695-14-9; (s)-4-(1-(2-(3-chloro-4-methoxyphenethyl)-5-(3,5-dimethylisoxazol-4-yl)-1h-benzo[d]imidazol-1-yl)propan-2-yl)morpholine; 2-[2-(3-chloro-4-methoxyphenyl)ethyl]-5-(dimethyl-1,2-oxazol-4-yl)-1-[(2S)-2-(morpholin-4-yl)propyl]-1H-1,3-benzodiazole; 2-[2-(3-Chloro-4-Methoxyphenyl)ethyl]-5-(3,5-Dimethyl-1,2-Oxazol-4-Yl)-1-[(2s)-2-(Morpholin-4-Yl)propyl]-1h-Benzimidazole; 2LO; C28H33ClN4O3; GTPL7529; SCHEMBL17512896; CHEMBL3622373; AOB4800; MolPort-035-395-859; BDBM188519; EX-A2159; ZINC96170456; s7256
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
72201027
ChEBI ID
CHEMBL3622373
TTD Drug ID
DMTLRGZ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
C 82 DMEWXFK Scleroderma 4A42 Phase 1/2 [3]
CCS1477 DM9UZM1 Solid tumour/cancer 2A00-2F9Z Phase 1/2 [4]
PRI-724 DM0HTEF Acute myeloid leukaemia 2A60 Phase 1/2 [5]
FT-7051 DMCK3OI Prostate cancer 2C82.0 Phase 1 [6]
Pyrrolo-pyrrolone derivative 6 DMBW208 N. A. N. A. Patented [7]
I-CBP112 DMQX3W6 Discovery agent N.A. Investigative [8]
ischemin DMM2I9G Discovery agent N.A. Investigative [9]
⏷ Show the Full List of 7 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
garcinol DM6B9ZG Discovery agent N.A. Investigative [10]
anacardic acid DMAS5BI Discovery agent N.A. Investigative [11]
I-CBP112 DMQX3W6 Discovery agent N.A. Investigative [12]
C646 DMCOQKH Discovery agent N.A. Investigative [13]
MG149 DM7V58G Discovery agent N.A. Investigative [14]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
CREB-binding protein (CREBBP) TTFRCTK CBP_HUMAN Inhibitor [2]
Histone acetyltransferase KAT6B (KAT6B) TTH4VJL KAT6B_HUMAN Inhibitor [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7529).
2 Bromodomains and their pharmacological inhibitors. ChemMedChem. 2014 Mar;9(3):438-64.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Targeting the p300/CBP Axis in Lethal Prostate Cancer. Cancer Discov. 2021 May;11(5):1118-1137.
5 Inhibition of Wnt/beta-catenin/CREB binding protein (CBP) signaling reverses pulmonary fibrosis. Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14309-14.
6 Clinical pipeline report, company report or official report of FORMA Therapeutics.
7 BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
8 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2734).
9 A small molecule binding to the coactivator CREB-binding protein blocks apoptosis in cardiomyocytes. Chem Biol. 2011 Apr 22;18(4):531-41.
10 Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene e... J Biol Chem. 2004 Aug 6;279(32):33716-26.
11 Small molecule modulators of histone acetyltransferase p300. J Biol Chem. 2003 May 23;278(21):19134-40.
12 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2735).
13 Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. Chem Biol. 2010 May 28;17(5):471-82.
14 6-alkylsalicylates are selective Tip60 inhibitors and target the acetyl-CoA binding site. Eur J Med Chem. 2012 Jan;47(1):337-44.